Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases

被引:58
作者
Lassau, N
Lamuraglia, M
Vanel, D
Le Cesne, A
Chami, L
Jaziri, S
Terrier, P
Roche, A
Leclere, J
Bonvalot, S
机构
[1] Inst Gustave Roussy, Dept Med Imaging, F-94805 Villejuif, France
[2] Inst Gustave Roussy, Dept Surg, F-94805 Villejuif, France
[3] Inst Gustave Roussy, Dept Pathol, F-94805 Villejuif, France
[4] Inst Gustave Roussy, Dept Med, F-94805 Villejuif, France
关键词
biochemotherapy; contrast medium; isolated limb perfusion; magnetic resonance imaging (MRI); soft tissue sarcoma (STS); ultrasound (US);
D O I
10.1093/annonc/mdi214
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The aim of this study was to prospectively evaluate the use of Doppler ultrasonography with perfusion software and contrast agent injection (DUPC) during isolated limb perfusion (ILP) with high-dose chemotherapy and TNF-alpha(biochemotherapy) in patients with locally advanced extremity soft tissue sarcoma (STS). Patients and methods: Fifty-two patients were prospectively included in this monocentric imaging trial. Three were excluded because the study was incomplete in two patients and one tumour did not exhibit any contrast uptake. DUPC was performed before ILP and on days 1, 7, 15, 30 and 60 after ILP. A total of 292 DUPC were performed on 55 target lesions in 49 evaluable patients. The percentage of contrast uptake was evaluated at each tumour site by two radiologists. The criterion tested was a decrease of more than 50% in intra-tumour contrast uptake compared to the pre-ILP examination. Results were compared with both MRI and histological analysis after resection of residual disease. Results: According to MRI and the histological analysis, 25 (51%) patients were good responders (no difference between the four treatment arms) with tumour necrosis exceeding 90% and 24 (49%) were poor responders. As of day +1, the accuracy of DUPC in predicting tumour response was 82% (18/25 good responders and 22/24 poor responders) increasing to 91% at day +7, 95% at day +15 and 96% at day +30. At day +15, DUPC was predictive of a good response in 100% of the cases. Conclusion: DUPC is a simple technique, allowing early prediction of tumour response after ILP. A new treatment planning scheme can be proposed based on the results of this study.
引用
收藏
页码:1054 / 1060
页数:7
相关论文
共 26 条
[1]  
ABUIN GG, 2004, P AN M AM SOC CLIN, V23, P823
[2]   Isolated limb perfusion with tumour necrosis factor-α and melphalan for unresectable bone sarcomas of the lower extremity [J].
Bickels, J ;
Manusama, ER ;
Gutman, M ;
Eggermont, AMM ;
Kollender, Y ;
Abu-Abid, S ;
Van Geel, AN ;
Lev-Shlush, D ;
Klausner, JM ;
Meller, I .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 1999, 25 (05) :509-514
[3]  
BONVALOT S, 2003, P AN M AM SOC CLIN, V22, P823
[4]   Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion [J].
de Wilt, JHW ;
ten Hagen, TLM ;
de Boeck, G ;
van Tiel, ST ;
de Bruijn, EA ;
Eggermont, AMM .
BRITISH JOURNAL OF CANCER, 2000, 82 (05) :1000-1003
[5]   Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives. [J].
Eggermont A.M. ;
ten Hagen T.L. .
Current Oncology Reports, 2001, 3 (4) :359-367
[6]  
EGGERMONT AM, 1999, P AN M AM SOC CLIN, V18, P535
[7]   Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas - The cumulative multicenter European experience [J].
Eggermont, AMM ;
Koops, HS ;
Klausner, JM ;
Kroon, BBR ;
Schlag, PM ;
Lienard, D ;
vanGeel, AN ;
Hoekstra, HJ ;
Meller, I ;
Nieweg, OE ;
Kettelhack, C ;
BenAri, G ;
Pector, JC ;
Lejeune, FJ .
ANNALS OF SURGERY, 1996, 224 (06) :756-765
[8]   Phase II trial of thalidomide in renal-cell carcinoma [J].
Escudier, B ;
Lassau, N ;
Couanet, D ;
Angevin, E ;
Mesrati, F ;
Leborgne, S ;
Garofano, A ;
Leboulaire, C ;
Dupouy, N ;
Laplanche, A .
ANNALS OF ONCOLOGY, 2002, 13 (07) :1029-1035
[9]  
Henri P, 2000, J RADIOL, V81, P465
[10]  
Hochedez P, 2003, J RADIOL, V84, P597